Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis

被引:15
|
作者
Castro, Rodolfo [1 ,2 ]
Perazzo, Hugo [3 ]
Artilles Mello Mendonca de Araujo, Leticia [1 ]
Gutierres, Isabella Goncalves [1 ]
Grinsztejn, Beatriz [3 ]
Veloso, Valdilea G. [3 ]
机构
[1] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, RJ, Brazil
[2] Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rio De Janeiro, RJ, Brazil
[3] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil
来源
PLOS ONE | 2020年 / 15卷 / 02期
关键词
REAL-WORLD; CARE; SOFOSBUVIR; SAFETY; REGIMENS; THERAPY; PROGRAM;
D O I
10.1371/journal.pone.0229143
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Direct-acting agents (DAAs) for hepatitis C virus (HCV) treatment are safe and highly effective. Few studies described the sustained virologic response rates of treatment conducted by non-specialists. We performed a systematic review and meta-analysis to evaluate the effectiveness of decentralized strategies of HCV treatment with DAAs. PubMed, Embase, Scopus and LILACS were searched until March-2019. Studies were screened by two researchers according to the following inclusion criteria: HCV treatment using DAAs on real-life cohort studies or clinical trials conducted by non-specialized health personnel. The primary endpoint was the sustained virologic response rate at week 12 after the end-of-treatment (SVR12), which is binary at the patient level. Data were extracted in duplicate using electronic-forms and quality appraisal was performed with the NIH Quality Assessment Tool. Heterogeneity was assessed by I-2 statistics. Random-effects meta-analysis models were used for pooling SVR12 rates. Publication bias was assessed using funnel plots. Among the 130 selected studies, nine papers were included for quantitative synthesis. The quality-appraisal was good for two, fair for three and poor for four studies. The pooled relative risk (RR) of SVR12 was not statistically different between decentralized strategy and treatment by specialists [RR = 1.05; 95% confidence interval (95% CI): 0.98-1.1; I-2 = 45% (95% CI: 0-84%), p = 0.145]. SVR12 rate for decentralized HCV treatment was 81% [SVR12 95% CI: 72-89%; I-2 = 93% (95% CI: 88-96%)] and 95% [SVR12 95%CI: 92-98%; I-2 = 77% (95% CI: 52-89%)] with intention to treat analysis and per-protocol analysis, respectively. SVR12 rates using DAAs managed by non-specialized health personnel were satisfactory and similar to those obtained by specialists. This new delivery strategy can improve access to HCV treatment, especially in resource-limited settings.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis
    Perazzo, Hugo
    Castro, Rodolfo
    Luz, Paula M.
    Banholi, Mariana
    Goldenzon, Rafaela, V
    Cardoso, Sandra W.
    Grinsztejn, Beatriz
    Veloso, Valdilea G.
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2020, 98 (03) : 188 - +
  • [2] Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis
    Kuo Chao Yew
    Quan Rui Tan
    Phei Ching Lim
    Wei Yang Low
    Chong Yew Lee
    [J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397 : 1421 - 1431
  • [3] Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis
    Yew, Kuo Chao
    Tan, Quan Rui
    Lim, Phei Ching
    Low, Wei Yang
    Lee, Chong Yew
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (03) : 1421 - 1431
  • [4] Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis
    Muecke, Marcus M.
    Herrmann, Eva
    Muecke, Victoria T.
    Graf, Christiana
    Zeuzem, Stefan
    Vermehren, Johannes
    [J]. LIVER INTERNATIONAL, 2019, 39 (09) : 1652 - 1660
  • [5] Efficacy and safety of direct-acting antivirals for hepatitis C in elderly patients: a systematic review and meta-analysis
    Muecke, Marcus
    Herrmann, Eva
    Muecke, Victoria Therese
    Graf, Christiana
    Zeuzem, Stefan
    Vermehren, Johannes
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E233 - E234
  • [6] Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals
    Jagpreet Chhatwal
    Tianhua He
    Maria A. Lopez-Olivo
    [J]. PharmacoEconomics, 2016, 34 : 551 - 567
  • [7] Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals
    Chhatwal, Jagpreet
    He, Tianhua
    Lopez-Olivo, Maria A.
    [J]. PHARMACOECONOMICS, 2016, 34 (06) : 551 - 567
  • [8] Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection
    Indolfi, Giuseppe
    Giometto, Sabrina
    Serranti, Daniele
    Bettiol, Alessandra
    Bigagli, Elisabetta
    De Masi, Salvatore
    Lucenteforte, Ersilia
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (07) : 1125 - 1133
  • [9] Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis
    Liu, Hui
    Yang, Xiao-Li
    Dong, Zhao-Ru
    Chen, Zhi-Qiang
    Hong, Jian-Guo
    Wang, Dong-Xu
    Li, Tao
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (09) : 1654 - 1665
  • [10] Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
    Frazzoni, Leonardo
    Sikandar, Usama
    Metelli, Flavio
    Sadalla, Sinan
    Mazzella, Giuseppe
    Bazzoli, Franco
    Fuccio, Lorenzo
    Azzaroli, Francesco
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)